ISRG240719C442500
- 9.60
- -3.63-27.44%
Intuitive Surgical Newsroom
Intuitive Surgical Analyst Ratings
BTIG Adjusts Price Target on Intuitive Surgical to $459 From $451, Maintains Buy Rating
Mizuho Adjusts Price Target on Intuitive Surgical to $440 From $390
Intuitive Surgical Analyst Ratings
Citigroup Adjusts Price Target on Intuitive Surgical to $512 From $462
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Catalyst Pharma (CPRX) and Eli Lilly & Co (LLY)
Piper Sandler Adjusts Price Target on Intuitive Surgical to $490 From $435, Overweight Rating Kept
Intuitive Surgical Analyst Ratings
Intuitive Surgical (ISRG) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Intuitive Surgical Analyst Ratings
Evercore ISI Adjusts Price Target on Intuitive Surgical to $425 From $385, Maintains In-line Rating
BTIG Adjusts Price Target on Intuitive Surgical to $451 From $421
Intuitive Surgical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Buy Rating Affirmed for Intuitive Surgical Amidst Ongoing Legal Challenges and Strong Financial Performance
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Telix Pharmaceuticals Ltd. (OtherTLPPF) and Intuitive Surgical (ISRG)
Intuitive Surgical (ISRG) Gets a Buy From Barclays
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG)